Retinal hypoxia also stimulates the production of vascular endothelial growth factors (VEGF), and anti-VEGF treatment has been shown to be effective in reducing diabetic macular edema and neovascularization, as well as delaying the progression of DR5. The gene discussed is VEGFA; the disease is diabetic macular edema.